Wyeth

Aventis Pharmaceuticals Inc.

Ronald Charles Bernotas

Steven Edward Lenicek

Derek Cecil Cole

Gavin David Heffernan

Albert Jean Robichaud

Andrew Fensome

Casey Cameron McComas

Thomas Joseph Commons

Edward George Melenski

Yinfa Yan

Michael Anthony Marella

Schuyler Adam Antane

Michael Byron Webb

Richard Page Woodworth, Jr

Hassan Mahmoud Elokdah

William Jospeh Lennox

Yanfang Li

Robert E McDevitt

David Zenan Li

Chi-Hsin Richard King

Paul Wayne Brown

Gary Emmons

Guangcheng Liu

Jay Edward Wrobel

Michael David Collini

Ping Zhou

Rayomand Jal Unwalla

Baihua Hu

John W Ullrich

Robert L Morris

Kevin G Liu

Alexander Greenfield

Geraldine Ruth McFarlane

Ping Cai

Christopher P Miller

Richard Dale Coghlan

Chia-Cheng Shaw

Ponnal Nambi

James Winfield Jetter

Cristina Grosanu

David H Kaufman

Jennifer Rebecca Lo

Robert R Singhaus, Jr

Elaine Quinet

Youchu Wang

Merle Elloso

Chung-Chiee Paul Wang

Zhi Wang

William Joseph Lennox

The present invention provides a compound of formula I and the use thereof for the treatment of a central nervous system disorder related to or affected by the 5-HT6 receptor. 

Substituted-3-sulfonylindazole derivatives as 5-hydroxytryptamine-6 ligands

Compounds of the following structure are described: wherein R-R, m, V, W, X, Y, Z and Q are described herein, or a pharmaceutically acceptable salt, tautomer, metabolite or prodrug thereof. These compounds are useful for treating a variety of hormone-related conditions including contraception, treating or preventing fibroids, endometriosis, dysfunctional bleeding, uterine leiomyomata, polycystic ovary syndrome, or hormone-dependent carcinomas, providing hormone replacement therapy, stimulating food intake or synchronizing estrus.

Oxazolidine derivatives as PR modulators

The present invention is directed to compounds of Formula I: which are modulators of the 5-hydroxtryptamine-6 and 5-hydroxytryptamine-2A receptors and which are inhibitors of norepinephrine reuptake. The compounds of the invention, and pharmaceutical composition thereof, are useful in the treatment of disorders related to or associated with the 5-hydroxytryptamine-6 and 5-hydroxtryptamine-2A receptors or with norepinephrine reuptake inhibition.

Sulfonyl substituted 1H-indoles as ligands for the 5-hydroxytryptamine receptors

Compounds of the following structure are described: wherein R, R, R, R, V, X, Y, Z and Q are described herein, or a pharmaceutically acceptable salt, tautomer, metabolite or prodrug thereof. These compounds are useful for treating a variety of hormone-related conditions including contraception, treating or preventing fibroids, endometriosis, dysfunctional bleeding, uterine leiomyomata, polycystic ovary syndrome, or hormone-dependent carcinomas, providing hormone replacement therapy, stimulating food intake or synchronizing estrus.

Oxazolidone derivatives as PR modulators

Compounds of the following structure are described: wherein R-R, R, m, V, W, X, Y, and Q are described herein, or a pharmaceutically acceptable salt, tautomer, metabolite or prodrug thereof. These compounds are useful for treating a variety of hormone-related conditions including contraception, treating or preventing fibroids, endometriosis, dysfunctional bleeding, uterine leiomyomata, polycystic ovary syndrome, or hormone-dependent carcinomas, providing hormone replacement therapy, stimulating food intake or synchronizing estrus.

Tricyclic oxazolidone derivatives useful as PR modulators

The present invention provides a compound of formula I and the use thereof in the therapeutic treatment of a central nervous system disorder related to or affected by the 5-HT6 receptor. 

Sulfonyldihydroimidazopyridinone compounds as 5-hydroxytryptamine-6 ligands

1-Heterocyclylalkyl-3-sulfonylindole or -indazole derivatives as 5-hydroxytryptamine-6 ligands

The present invention provides a compound of formula I and the use thereof for the therapeutic treatment of disorders relating to or affected by the 5-HT6 receptor. 

1-(aminoalkyl)-3-sulfonylazaindoles as 5-hydroxytryptamine-6 ligands

Azaindolylalkylamine derivatives as 5-hydroxytryptamine-6 ligands

Heterocyclyl-3-sulfonylazaindole or -azaindazole derivatives as 5-hydroxytryptamine-6 ligands

This invention provides compounds of formula I that are useful in the treatment or inhibition of LXR mediated diseases.

Quinolines and pharmaceutical compositions thereof

The present invention provides a compound of formula I and the use thereof in the therapeutic treatment of disorders related to or affected by the 5-HT6 receptor. 

Heterocyclyl-3-sulfonylindazoles as 5-hydroxytryptamine-6 ligands

Sulfonyldihydrobenzimidazolone compounds as 5-hydroxytryptamine-6 ligands

Compounds of the following structure are described: wherein R-R, m, V, X, Y, Z and Q are described herein, or a pharmaceutically acceptable salt, tautomer, metabolite or prodrug thereof. These compounds are useful for treating a variety of hormone-related conditions including contraception, treating or preventing fibroids, endometriosis, dysfunctional bleeding, uterine leiomyomata, polycystic ovary syndrome, or hormone-dependent carcinomas, providing hormone replacement therapy, stimulating food intake or synchronizing estrus.

Oxazinan-2-one derivatives useful as PR modulators

Indolylalkylamine metabolites as 5-hydroxytryptamine-6 ligands

Growing community of inventors

Royersford, PA, United States of America

Ronald Charles Bernotas